Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8028545 | 0.84 | KDM4E (0.37) | MAPTKDM4EALDH1A1MEN1GAA | |
| SCHEMBL8034375 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1MEN1GAAKMT2A | |
| SCHEMBL930275 | 0.80 | NR1H2 (0.42) | MAPTKDM4EALDH1A1MEN1GAA | |
| SCHEMBL929547 | 0.78 | MAPT (0.35) | MAPTHRH3ALDH1A1SMN1; SMN2KCNK3 | |
| SCHEMBL12905210 | 0.72 | NR1H2 (0.41) | MAPTHRH3KDM4ESMN1; SMN2KCNK3 | |
| SCHEMBL3819952 | 0.70 | MAPT (0.34) | MAPTKDM4EALDH1A1MEN1GAA | |
| SCHEMBL3820003 | 0.70 | ALDH1A1 (0.34) | MAPTKDM4EALDH1A1MEN1GAA | |
| SCHEMBL12905189 | 0.66 | KDM4E (0.33) | MAPTKDM4EALDH1A1MEN1GAA | |
| SCHEMBL928282 | 0.66 | CHRM3 (0.38) | MAPTKCNK3TP53MLYCD | |
| SCHEMBL930651 | 0.64 | NR1H2 (0.42) | MAPTKDM4EALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095254-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | GRM5, GRIK5, GRK5 | MAPT 2144/4885HRH3 748/4885KDM4E 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.